You are here

Home

ONL Therapeutics, Inc.

Company Information
Address
1600 Huron Pkwy 2nd Fl
Ann Arbor, MI 48109-5001
United States


http://www.onltherapeutics.com
Information

UEI: WVYFPECFBHY8

# of Employees: 5
Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No

Award Charts




Award Listing

  • Record 1 TO 5

  1. Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD

    Amount: $1,098,854.00

    PROJECT SUMMARY / ABSTRACT Age-related macular degeneration (AMD) is the leading, and due to the aging baby boomers, a growing cause of irreversible vision loss in the United States, and is strongly a ...

    STTRPhase II2020Department of Health and Human Services National Institutes of Health

  2. Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD

    Amount: $300,202.00

    PROJECT SUMMARYABSTRACT Age related macular degenerationAMDis the leadingand due to the aging baby boomersa growing cause of irreversible vision loss in the United Statesand is strongly associated wit ...

    STTRPhase I2018Department of Health and Human Services National Institutes of Health

  3. De-risking ONL1204 to enable venture capital investment for first-in-human clinical trials

    Amount: $1,219,466.00

    PROJECT SUMMARYABSTRACTRetinal degenerative disease and injury are among the leading causes of irreversible vision loss and blindness in the United States and the developed worldaffecting hundreds of ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health

  4. Preclinical development of ONL-101 for photoreceptor protection in retinal detach

    Amount: $1,377,371.00

    DESCRIPTION provided by applicant Death of photoreceptor cells is a consequence of many acute as well as chronic retinal diseases which lead to severe vision loss in patients If photoreceptors co ...

    SBIRPhase II2014Department of Health and Human Services National Institutes of Health

  5. Prevention of photoreceptor cell death with intravitreal Fas-receptor antagonist

    Amount: $421,640.00

    DESCRIPTION (provided by applicant): Death of photoreceptor cells is a consequence of many acute as well as chronic retinal diseases which lead to severe vision loss in patients. If photoreceptors cou ...

    SBIRPhase I2012Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government